Latent alpha1-antichymotrypsin. A molecular explanation for the inactivation of alpha1-antichymotrypsin in chronic bronchitis and emphysema.
about
Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational diseaseTopography of a 2.0 Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational diseaseLatent S49P neuroserpin forms polymers in the dementia familial encephalopathy with neuroserpin inclusion bodiesPolymerization of plasminogen activator inhibitor-1.Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.Novel secretory vesicle serpins, endopin 1 and endopin 2: endogenous protease inhibitors with distinct target protease specificities.Extending the capabilities of targeted molecular dynamics: simulation of a large conformational transition in plasminogen activator inhibitor 1.Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibodyTryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1.Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1.Serpins (serine protease inhibitors).Characterization of the necrotic protein that regulates the Toll-mediated immune response in Drosophila.Mutational analysis of plasminogen activator inhibitor-1.The selective inhibition of serpin aggregation by the molecular chaperone, alpha-crystallin, indicates a nucleation-dependent specificity.Moraxella-dependent alpha 1-antichymotrypsin neutralization: a unique virulence mechanism.The cleaved and latent forms of antithrombin are normal constituents of blood plasma: a quantitative method to measure cleaved antithrombin.A Kinetic Mechanism for the Polymerization of α1-Antitrypsin
P2860
Q24652121-A842B142-4FEE-4A75-8491-654B4AF99332Q27626230-EAE502BB-9AC3-4AF9-84A0-011DBAF06D5FQ28303740-D7A9F241-3EF6-4AFE-97C3-B1709143CA9EQ31645732-0DB9AFF1-25FF-4200-B4D5-35693C84DBC1Q34149948-E70155AE-17AC-4413-9A1A-22C1F200E770Q35000714-A569D74D-7D6C-4CC9-8636-971ADE4723BFQ38271704-0ECA3EB8-D691-4E3D-A6CF-397393E7494BQ38933451-C2127901-BD91-4C0E-97FA-6CE18C0C842DQ40243697-AF388E54-BF01-4CC5-B877-49B4CC6DCFD5Q41818079-3C1FDF05-3FE1-4FA6-9A68-FEE573E715B8Q41857439-D31907C1-4393-4496-A19C-116A0C37E1A3Q42169741-94C518EF-8879-4C47-AE35-5B9F5DC66E45Q44203913-04912CB4-0630-48A0-B918-D220E0DB4E04Q44402632-D8DE1EC0-5F54-4EE0-81E6-22ED34ABD023Q44590833-D053A828-9605-48AC-8D6A-D7B85F4D44CAQ45225620-1A1AB4B0-07D1-439A-9468-0802D9EF7BF0Q46892245-33A2328E-B8DE-46C6-A8ED-A50F753FF1C9Q57980265-30B5F8E0-7F54-4525-A868-B47ED10EF24D
P2860
Latent alpha1-antichymotrypsin. A molecular explanation for the inactivation of alpha1-antichymotrypsin in chronic bronchitis and emphysema.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Latent alpha1-antichymotrypsin ...... onic bronchitis and emphysema.
@en
Latent alpha1-antichymotrypsin ...... onic bronchitis and emphysema.
@nl
type
label
Latent alpha1-antichymotrypsin ...... onic bronchitis and emphysema.
@en
Latent alpha1-antichymotrypsin ...... onic bronchitis and emphysema.
@nl
prefLabel
Latent alpha1-antichymotrypsin ...... onic bronchitis and emphysema.
@en
Latent alpha1-antichymotrypsin ...... onic bronchitis and emphysema.
@nl
P2860
P356
P1476
Latent alpha1-antichymotrypsin ...... onic bronchitis and emphysema.
@en
P2093
P2860
P304
P356
10.1074/JBC.273.6.3695
P407
P577
1998-02-01T00:00:00Z